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Abstract: The goals of epilepsy therapy are to achieve seizure freedom while minimizing adverse effects of treatment. 
However, producing seizure-freedom is often overemphasized, at the expense of inducing adverse effects of treatment. All 
antiepileptic drugs (AEDs) have the potential to cause dose-related, “neurotoxic” adverse effects (i.e., drowsiness, fatigue, 
dizziness, blurry vision, and incoordination). Such adverse effects are common, especially when initiating AED therapy 
and with polytherapy. Dose-related adverse effects may be obviated in most patients by dose reduction of monotherapy, 
reduction or elimination of polytherapy, or substituting for a better tolerated AED. Additionally, all older and several 
newer AEDs have idiosyncratic adverse effects which usually require withdrawal in an affected patient, including serious 
rash (i.e., Stevens-Johnson Syndrome, toxic epidermal necrolysis), hematologic dyscrasias, hepatotoxicity, teratogenesis 
in women of child bearing potential, bone density loss, neuropathy, and severe gingival hyperplasia. Unfortunately, occur-
rence of idiosyncratic AED adverse effects cannot be predicted or, in most cases, prevented in susceptible patients. This 
article reviews a practical approach for the definition and identification of adverse effects of epilepsy therapies, and re-
views the literature demonstrating that adverse effects result in detrimental quality of life in epilepsy patients. Strategies 
for minimizing AED adverse effects by reduction or elimination of AED polytherapy, appropriately employing drug-
sparing therapies, and optimally administering AEDs are outlined, including tenets of AED selection, titration, therapeutic 
AED laboratory monitoring, and avoidance of chronic idiosyncratic adverse effects. 
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QOL: A NEW TREATMENT PARADIGM IN EPILEP-
SY 
  Although analysis of quality of life (QOL) in epilepsy 
began later than many other medical fields, an ever growing 
body of epilepsy QOL research has accumulated over the last 
decade. A review of all the validated instruments for re-
search and clinical use in epilepsy is beyond the scope of this 
article; two excellent recent reviews addressing the range of 
available tools and their relative advantages and potential 
uses are available for the interested reader [16,28].
 In gener-
al, QOL research emphasizes measures of a patient’s general 
wellness in a particular disease state, incorporating a multi-
dimensional health assessment of physical, psychological, 
and social domains affected by the illness and its treatment; 
these domains comprise most commonly utilized instruments 
in epilepsy research and practice, the QOLIE-89, QOLIE-31, 
and QOLIE-10 [28].
 
  Epilepsy QOL research has re-emphasized the impor-
tance of producing seizure-freedom as a principle goal for all 
patients, but has also revealed that the interictal state is a 
principle determinant of a patient’s own perceived quality of 
life; in addition to seizures themselves, a patient’s daily 
functioning, cognitive status, mood states, social functioning, 
and the closely related factor of perceived adverse treatment 
effects determine how a patient feels about their overall 
QOL. QOL research in epilepsy has reshaped priorities in 
epilepsy care, calling for clinicians to maintain vigilance   
 
*Address correspondence to this author at Department of Neurology, Mayo 
Clinic, 200 First Street Southwest, Rochester, MN 55905, USA; Tel: (507) 
538-1038; Fax: (507) 284-4074; E-mail: StLouis.Erik@mayo.edu 
over the patient’s interictal status in the monitoring of mood, 
cognition, social functioning, and adverse effects in addition 
to seizure burden. 
DEFINING AND IDENTIFYING ADVERSE EFFECTS 
OF EPILEPSY THERAPIES 
  An adverse effect of therapy may be defined as any clini-
cal symptom, sign, or laboratory dyscrasia which is deemed 
undesirable to the patient, the physician, or both. Adverse 
effects, while always unintended, are not entirely unexpected 
in epilepsy care; adverse effects are unfortunately common, 
reported in 40-50% of epilepsy patients receiving monothe-
rapy AED treatment [2,21]. Most common are dose-related 
adverse effects, sometimes termed “neurotoxic” adverse ef-
fects, which may include (but are certainly not limited to) 
drowsiness, dizziness, fatigue, headache, blurry or double 
vision, impaired concentration or memory, or incoordination. 
Some AEDs are apt to produce certain characteristic adverse 
effects. A list of AEDs and common adverse effects (which 
is by no means exhaustive or comprehensive) is given in 
Table 1. 
  Identifying AED toxicity in affected patients is proble-
matic for several reasons. Some patients may have grown 
used to feeling ill while receiving AED therapy and compla-
cently accept adverse effects as a natural consequence of 
their treatment. Additionally, patients are often understanda-
bly reluctant to “make waves” during clinic visits. Patients’ 
fears of ongoing seizures tend to overshadow complaints 
about medication toxicity, and conversely, seizure-free pa-
tients are often too comfortable with and grateful for their 
outcomes to broach the risk of lowering or withdrawing 
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  Furthermore, patient reticence to raise concerns over tox-
icity is compounded by physicians’ preoccupation with as-
sessment of seizure events (perhaps driven in part by overly 
busy clinics which discourage thorough communication), 
leading physicians to focus only on seizure histories while 
neglecting to inquire about AED toxicity and other important 
related interictal factors. Physicians also typically place 
greater concern about serious idiosyncratic adverse effects 
despite their infrequency due to fear of litigation; instead of 
being vigilant to bedside measures of common adverse ef-
fects, physicians may instead too often focus on clinical la-
boratory values such as AED blood levels, chemistries, liver 
function testing, and complete blood counts. However, while 
a valuable adjunct to guide clinical decision-making, AED 
blood levels are neither a fail-safe for detecting clinical tox-
icity or ensuring therapeutic seizure-freedom, and uncertain-
ty exists as to the interpretation and clinical value of blood 
levels for many of the newer AEDs. 
  The availability of a rapid, efficient, and accurate tool for 
identifying common, dose-related, potentially remediable 
adverse effects in the office setting would greatly assist cli-
Table 1.  Properties of the AEDs 
Older AEDs  Spectrum of  
Effect 
Daily Adult Do-
sage/Interval 
Levels (uG/mL)  Usual Adverse 
Effects 
Severe  
Idiosyncratic 
Toxicities 
Interactions 
Carbamazepine  Partial  400-1600+ mg (BID-
QID) 
4-12+ Diplopia,  dizziness, 
ataxia, hyponatre-
mia 
Yes Bidirectional; 
(AEDs, OC, AC, 
many) 
Ethosuximide  Absence  500-1500+ mg (BID)  40-100+ Nausea.  sedation  Yes  Unidirectional 
Phenobarbital Partial  90-180+  mg  (qD) 15-40  Sedation,  Psycho-
motor slowing 
Yes Bidirectional  (AEDs, 
OC, AC, many) 
Phenytoin Partial  200-400+  mg  (qD-BID)   8-20+  Sedation, dizziness, 
ataxia, gingival 
hyperplasia 
Yes Bidirectional 
(AEDs, OC, AC, 
many) 
Primidone  Partial  500-1500+ mg (BID-
TID) 
5-12 (measure 
phenobarbital) 
Sedation, psycho-
motor slowing 
Yes Bidirectional 
(AEDs, OC, AC, 
many) 
Valproate  Broad  750-2500+ mg (qD-TID)  50-100+  Nausea, tremor, hair 
loss, weight gain 
Yes Bidirectional 
(AEDs) 
Newer AEDs 
Felbamate Broad  1800-4800+  mg  (BID-
TID) 
30-100+ Irritability,  insom-
nia, weight loss 
Yes Bidirectional 
(AEDs, OC, AC) 
Gabapentin  Partial  900-3600+ mg (TID-
QID) 
4-20++ Sedation,  dizziness, 
weight gain 
No None 
Lacosamide Partial,  potentially 
broad 
200-600+ mg   ?  Sedation, fatigue  ?  None known 
Lamotrigine Broad  300-600+  mg  (qD-BID)  4-20+ Dizziness,  rash  Yes    Bidirectional 
(AEDs, OC) 
Levetiracetam  Broad  1000-3000++ mg (BID)  5-40++ Sedation,  dizziness  No  None 
Oxcarbazepine  Partial  600-3600+ mg (BID) 10-40+  (MHD)  Sedation, dizziness 
hyponatremia 
Yes Bidirectional 
(AEDs, OC) 
Rufinamide Broad  400-3200+  mg  daily  ? Sedation, diarrhea  ?  Bidirectional   
Tiagabine Partial  16-64  mg  (BID-TID)  100-300  ng/mL Sedation,  dizziness  No  Unidirectional 
Topiramate Broad  100-600+  mg  (qD-BID) 10-20+ Sedation,  cognitive 
complaints, pares-
thesias, weight loss, 
rare nephrolithiasis 
No Bidirectional(AEDs, 
OC at high doses) 
Zonisamide Broad  100-600+  mg  (qD-BID) 10-40+  Sedation,  paresthe-
sias, weight loss, 
rare nephrolithiasis 
Yes Unidirectional 
AED = antiepileptic drug; uG/mL= micrograms/milliliter; + = higher doses/levels often additionally effective, as tolerated; ++ = considerably higher doses/levels sometimes addi-
tionally effective in intractable patients, as tolerated; MHD = 10, 11; Monohydroxyderivative active metabolite of oxcarbazepine; nG/mL = nanograms/milliliter.  Interactions: Unidi-
rectional indicates that other AEDs or drugs may affect this AED; Bidirectional indicates that other drugs may affect this AED, and this AED affects other drugs; OC=oral contracep-
tives, AC=anticoagulants; many=many other non-AEDs. 108    Current Neuropharmacology, 2009, Vol. 7, No. 2  Erik K. St. Louis 
nicians and patients alike. Fortunately, such a tool exists: the 
Adverse Event Profile (Table 2) [2,3]. 
AED ADVERSE EFFECTS ARE A PRINCIPLE DE-
TERMINANT OF QOLIE 
 Antiepileptic  drug  adverse  effects are a principle deter-
minant of QOL in epilepsy patients. Proactive, quantitative 
assessment of adverse effects enables their identification and 
appropriate alteration of AEDs to reduce adverse effects. A 
recent randomized controlled trial of a rapid diagnostic tool 
for identification and quantification of AED adverse effects 
in a clinical office setting has been conducted, which eva-
luated the self-completed Adverse Event Profile (AEP, Table 
2) questionnaire [11]. This study convincingly demonstrated 
that clinicians who had access to information from the AEP 
more frequently adjusted their patients’ AEDs, resulting in 
improved patient quality of life, without sacrificing seizure 
control. The authors concluded that routine use of the AEP in 
epilepsy clinics may aid clinicians in identifying adverse 
effects of AED therapy, and consequently guide them in ad-
justing the AED regimen appropriately to obviate adverse 
effects. This research suggests that the clinicians’ well inten-
tioned quest to produce seizure-freedom often leads to over-
treatment with AEDs; pushing AED doses ever upward, and 
adding AED upon AED in a spiraling fashion may have clear 
negative consequences for quality of life. 
MINIMIZING AED ADVERSE EFFECTS 
  AEDs should be adjusted to achieve the clinical goals of 
seizure-freedom without adverse effects. This may be a deli-
cate balancing act for some patients, since all AEDs have the 
potential to cause dose-related, “neurotoxic” adverse effects. 
Fortunately, adverse effects may be obviated in most patients 
by dose reduction, reducing or eliminating AED polytherapy, 
or substituting for a better tolerated AED. 
  One relatively simple solution to avoiding or minimizing 
AED adverse effects is a class switch from an older to a 
newer AED in patients who are experiencing toxicity on 
their current therapy, and selecting newer AEDs for new 
onset epilepsy patients who may be vulnerable to the devel-
Table 2.  Adverse Events Profile.  
The instructions to patient for the Adverse Events Profile are as follows: During the past four weeks, have you had any of the problems or 
adverse effects listed below?  For each item, if it always or often has been a problem, circle 4; if it sometimes has been a problem, circle 3; 
and so on.  Please answer ever item. 
  Always/Often Sometimes  Rarely  Never 
Unsteadiness 4  3  2  1  
Tiredness 4  3  2  1  
Restlessness 4  3  2  1  
Feelings of aggression 4  3  2  1  
Nervousness and/or ag-
gression 
4 3  2  1  
Headache 4  3  2  1  
Hair loss 4  3  2  1  
Problems with skin (eg 
acne, rash) 
4 3  2  1  
Double or blurred vision 4  3  2  1  
Upset stomach 4  3  2  1  
Difficulty in concentration 4  3  2  1  
Trouble with mouth or 
gums 
4 3  2  1  
Shaky hands 4  3  2  1  
Weight gain 4  3  2  1  
Dizziness 4  3  2  1  
Sleepiness 4  3  2  1  
Depression 4  3  2  1  
Memory problems 4  3  2  1  
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opment of AED toxicity. Older AEDs result in adverse ef-
fects of treatment in nearly half of patients [16,28]. Fortu-
nately, the availability of several newer AEDs offers im-
proved tolerability and safety profiles, helpful qualities that 
the clinician may employ to minimize adverse effects in epi-
lepsy care.
 Since 1990, eleven new antiepileptic drugs rather 
than nine (AEDs; felbamate, gabapentin, lacosamide, lamo-
trigine, levetiracetam, oxcarbazepine, pregabalin, rufina-
mide, tiagabine, topiramate, and zonisamide) have been ap-
proved by the Food and Drug Administration (FDA) based 
initially on adjunctive therapy pivotal trial designs. 
  Several controlled trials have suggested that newer AEDs 
possess superior tolerability to older AEDs, especially in 
patient populations with specific vulnerability to AED toxici-
ty such as the elderly [5,32]. Unfortunately, higher cost con-
tinues to limit access of newer AEDs for many patients, but 
availability of reliable generic formulations of many newer 
AEDs has increased recently, which could largely obviate 
this barrier. 
  Another principle for avoiding and minimizing adverse 
effects is to employ monotherapy at the lowest effective dose 
whenever possible, and reserve AED polytherapy at an ac-
ceptable total drug load for refractory epilepsy. While all 
older AEDs were “grandfathered” in their indication for mo-
notherapy treatment of epilepsy by FDA on the basis of 
comparator trial data and longstanding clinical experience, 
monotherapy approval and data supporting use for most 
newer AEDs is more limited. Gabapentin, oxcarbazepine, 
and lamotrigine possess randomized controlled trial evidence 
for monotherapy treatment of partial-onset seizures and topi-
ramate has evidence for monotherapy use in new onset epi-
lepsy [9].
 Although felbamate possess monotherapy efficacy 
data, its sole use currently is in brittlely refractory epilepsy, 
given its risk of idiosyncratic toxicities. 
REDUCING POLYTHERAPY REDUCES ADVERSE 
EFFECTS 
  AED polytherapy should be reserved for use in refractory 
epilepsy. When polytherapy is necessary to achieve seizure 
control, utilizing the lowest possible drug load (the lowest 
numbers and doses of AEDs) is desirable. Many medically 
refractory epilepsy patients require chronic polytherapy, and 
the recent AAN/AES Practice Guidelines for the treatment of 
refractory epilepsy stated that all newer FDA-approved 
AEDs have Class 1 evidence for adjunctive treatment of re-
fractory partial-onset seizures in adults, and there is ample 
evidence to conclude that lamotrigine, oxcarbazepine, and 
topiramate are effective for the treatment of refractory partial 
seizures in children [10]. While no good evidence for specif-
ic AED polytherapy combinations exists, augmenting mono-
therapy with an AED offering a different or complementary 
mechanism of action may be considered. 
  Eleven new antiepileptic drugs rather than nine. When 
polytherapy is prescribed, great care must be taken to avoid 
excessive drug dosing and drug-drug interactions that may 
increase clinical toxicity through pharmacokinetic factors. 
Considerable research has demonstrated that the most delete-
rious result of polytherapy is an increased risk for develop-
ment of adverse effects, including pharmacodynamic dose-
related neurotoxic effects, severe life threatening rash with 
combined lamotrigine and valproate, and teratogenic effects 
in children born to pregnant women receiving AED polythe-
rapy. A recent survey of patients with epilepsy demonstrated 
that central nervous system-related adverse effects, especial-
ly memory complaints and fatigue, appear to be most fre-
quent overall, and that polytherapy was more frequently as-
sociated with these adverse effects than monotherapy [6].
 
  Unfortunately, only a small number of refractory patients 
can be rendered seizure-free with AED polytherapy, al-
though some patients benefit substantially by reduction of 
seizure burden. A recent pivotal prospective observational 
study demonstrated that only 3% of patients who fail two 
sequential initial monotherapies are subsequently rendered 
seizure-free by polytherapy [13].
  Since AED polytherapy 
only rarely results in seizure freedom, the overall philosophy 
of AED therapy for refractory epilepsy necessarily shifts 
from effecting seizure-freedom to the more modest goal of 
seizure palliation. While no epilepsy care should be rendered 
with a defeatist attitude, a practical realization that the re-
fractory patient is highly unlikely to benefit from overly ag-
gressive AED dosing may prevent overtreatment of the pa-
tient with ever escalating doses and numbers of AEDs in a 
polytherapy regimen. Instead, establishing that a patient has 
refractory epilepsy suggests the need for proactive explora-
tion of non-pharmacologic treatment alternatives to AED 
therapy that offer the potential benefits of reducing AED 
drug load and minimizing adverse effects. 
DRUG SPARING THERAPIES MAY ENABLE AED 
REDUCTION 
  Failure to produce seizure control after even one well-
tolerated, optimally administered monotherapy AED is an 
ominous prognostic feature that may portend medical intrac-
tability in many patients [14]. After failure of one or two 
AED monotherapies, patients with epilepsy should receive 
strong consideration of additional diagnostic evaluation for 
non-pharmacological therapies, including state-of-the art 
neuroimaging to detect lesional epileptogenic pathology that 
is potentially amenable to surgical resection, and ictal video-
electroencephalography (vEEG) for definitive epilepsy syn-
drome classification and possible localization. Potentially 
“drug sparing” non-pharmacologic therapies may afford op-
portunities to reduce AED adverse effects by minimizing 
AED drug numbers and dosages, thereby improving QOL. 
Currently available “drug-sparing” therapies include epilepsy 
surgery, the vagus nerve stimulator, dietary therapies, and 
exploration of co-morbid primary sleep disorders that may 
aggravate epilepsy. However, each of these therapies have 
their own unique set of potential adverse effects that are 
quite different from those of the AEDs to consider. 
  The superiority of epilepsy surgery over medical therapy 
for well-localized mesial temporal lobe epilepsy, the most 
common refractory partial epilepsy syndrome, has been well 
established in a randomized controlled trial [38]. Patients 
with mesial temporal lobe epilepsy were randomized to ante-
rior temporal lobectomy surgery or best medical therapy. At 
one-year, an intention to treat analysis demonstrated supe-
riority of surgery; 58% of patients randomized to surgical 
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those who received surgery), whereas only 8% of patients 
became seizure-free on medical management. Patent QOL 
was also improved significantly in the surgical group com-
pared with the medical group, although the persistence of 
this difference weaned by the completion of the trial. A re-
cent metaanalysis yielded similar data on seizure-control for 
temporal lobe resections, but suggested less robust outcomes 
varying between 27-46% patients rendered seizure-free fol-
lowing extratemporal resections [8,37].
 Importantly, numer-
ous studies have shown decreases in patient drug load when 
comparing pre-operative to post-operative dosages and num-
bers of AEDs. Adverse effects of epilepsy surgery include a 
minor risk (between 1-5% in major series) of major acute 
surgical complications such as hemorrhage, infarction, or 
infection, or of memory, language, visual, motor, or somato-
sensory functional loss depending upon the locali-zation of 
the surgical epileptic focus. Some patients with refractory 
partial epilepsy are not suitable epilepsy surgical candidates 
due to diffuse or unlocalizable epileptic foci, while others 
may have epileptic foci overlapping critical cerebral func-
tional cortex. Still others may choose not to undergo brain 
surgery despite suitable candidacy. In these cases, other op-
tions may still exist. 
  The vagus nerve stimulator (VNS) is a FDA approved 
device as an adjunctive treatment for refractory partial-onset 
onset seizures. Long-Term follow-up outcome data suggests 
that over 40% of patients experience a 50% or greater reduc-
tion in their seizures [24]. More recent evidence suggests 
that up to 15% of patients may become seizure-free when the 
device is implanted in patients with milder refractory epilep-
sy (epilepsy duration less than 5 years, having failed 4 or 
fewer previous AED trials) [31]. There is no current evi-
dence based guideline for the best timing of VNS placement, 
but most epileptologists reserve VNS for patients who are 
not resective surgery candidates or who refuse surgery, and 
for patients who have filled several older and new AEDs, 
given that seizure free efficacy is less with VNS than with 
resection surgery for carefully selected well-localized pa-
tients, and generally efficacy of VNS to that seen with 
AEDs. However, VNS offers additional benefits to seizure 
burden reduction alone in many patients; VNS therapy has 
been noted to improve patient QOL, possibly by improving 
important determinants of QOL in epilepsy such as alertness, 
mood and memory which may be due in part to successful 
reduction of AED loads [7,15]. A distinguishing advantage 
of VNS therapy is its lack of sedating or neurotoxic adverse 
effects; instead, VNS adverse effects such as throat discom-
fort or vocal hoarseness are usually mild, temporary, and 
related only to the stimulation-on duty cycle, and VNS ad-
verse effects are usually easily mitigated by alterations in 
stimulation parameter settings. Predictors of which precise 
epilepsy localizations and etiologies are most likely to bene-
fit from VNS, and the optimal dosing of the device once it 
has been implanted, are yet to be defined in prospective clin-
ical trials. 
  Specialized diets may be a useful adjunctive treatment for 
epilepsy. The best studied of these is the ketogenic diet. The 
ketogenic diet is a high fat, low protein, low carbohydrate 
diet that induces systemic ketosis, which has an antiepilepto-
genic effect on the brain. The ketogenic diet is most often 
successfully employed in children, but may also be tried in 
adolescents and adults. Unfortunately, unless rigid com-
pliance is assured, the ketogenic diet produces little benefit 
and, in general, most adolescents and adults have limited 
tolerance of the diet. However, highly motivated and despe-
rately refractory epilepsy patients may benefit from the keto-
genic diet. An alternative that is often more tolerable, but not 
yet robustly studied, is the modified Atkins diet, a high fat, 
moderate protein, low carbohydrate diet that induces mild 
ketosis. The risk of inducing undesirable lipid abnormalities, 
metabolic states, and other long-term health effects of these 
dietary therapies also remain unclear. 
  Identifying and treating seizure aggravators is also an 
important consideration. Recent studies have suggested that 
obstructive sleep apnea (OSA) is a frequent co-morbidity in 
refractory epilepsy, and a pilot treatment trial of nasal conti-
nuous positive airway pressure (nCPAP) in patients with 
refractory epilepsy and co-morbid OSA showed substantial 
seizure reduction without alteration of AED therapy [17-19]. 
Primary sleep disorders such as OSA, restless legs syn-
drome, and periodic limb movements of sleep may fragment 
sleep and worsen seizure burden in patients with refractory 
epilepsy. If a primary sleep disorder is suspected, a diagnos-
tic polysomnogram should be ordered, and aggressive treat-
ment for any primary sleep disorder discovered should be 
initiated. One limitation of therapy for OSA is that adverse 
effects and poor tolerability of nCPAP therapy are common; 
tolerability and potential risks of nCPAP therapy in those 
with co-morbid epilepsy have not been reported and merit 
prospective investigation. 
PRACTICAL STRATEGIES FOR OPTIMAL AED 
ADMINISTRATION TO MINIMIZE ADVERSE EF-
FECTS 
  Guidelines for choosing and optimally administering 
epilepsy therapies are currently lacking. Until evidence-
based guidelines are developed, optimal selection and ad-
ministration of epilepsy therapies must be highly individua-
lized by synthesizing available data and patient qualities and 
preferences. AED selection, titration, target dosage, basic 
pharmacokinetic properties, potential AED and non-AED 
drug interactions, therapeutic AED laboratory monitoring, 
and avoidance of chronic idiosyncratic adverse effects are all 
considerations when attempting to minimize adverse effects 
of AED administration. There are currently no clear evidence 
based algorithms to guide these important factors in AED 
treatment. Nonetheless, common treatment principles under-
lie the choosing, dosing, sequencing, and monitoring of AED 
therapy in epilepsy care. While a comprehensive guide to 
employing AED therapy is beyond the scope of this article, 
several basic principles for optimal AED administration in-
clude: 
-  Choose AED therapy appropriate for the epilepsy syn-
drome; 
-  Consider patient characteristics and co-morbidities when 
choosing AEDs; 
-  Employ AED monotherapy at the lowest effective dosage 
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-  Reserve AED polytherapy (combining two or more 
AEDs) for refractory patients and minimize total drug 
load to limit adverse effects; 
-  Treat according to the patient’s clinical response, not the 
AED level; 
-  Monitor for long-term complications of older AED ther-
apy and consider withdrawal of therapy when appropri-
ate; and 
-  Choose affordable AED therapy. 
  A few of these points which are particularly important for 
avoiding and minimizing adverse effects are next considered. 
AED SELECTION 
  A first general principle in AED choice and usage is to 
employ AED monotherapy whenever possible, since mono-
therapy is just as effective, or more effective, than polythera-
py. Monotherapy limits the potential for adverse effects and 
drug interactions. Specific AEDs are itemized with accom-
panying information on clinical spectrum of uses, pharmaco-
kinetics, typical dosing and blood levels, and cardinal ad-
verse effects in Table 1. When choosing and utilizing AEDs, 
a considerable amount of pharmacological knowledge and 
clinical wisdom is necessary for successful patient outcomes. 
Patient’s characteristics such as age, sex, co-morbidities, and 
co-existing medications are important determinants of proper 
drug selection and use. These factors most frequently guide 
which AED may have the most desirable pharmacokinetic 
and phamacodynamic properties to avoid the development of 
undesirable adverse effects, and examples of patient charac-
teristics that impact on AED selection are now discussed. 
  Older patient age is a factor suggesting a heightened vul-
nerability to the development of dose-related neurotoxic ad-
verse effects. Several recent studies have shown that newer 
AEDs are better tolerated in the elderly [5, 32]. Female sex is 
an important determinant of AED selection; women usually 
have lower bone density and may therefore be most vulnera-
ble to development of osteopenia, and growing evidence now 
suggests that several older AEDs may accelerate bone loss. 
In women of childbearing potential, AEDs that are asso-
ciated with teratogenicity and which may interact with hor-
monal contraceptives also merit cautious use, and may be 
best avoided. Patient co-morbidities may affect the choice of 
an AED. For example, weight is an important consideration. 
Valproate, pregabalin, and carbamazepine may contribute to 
weight gain, while topiramate and zonisamide may include 
weight loss among their “adverse effect” profile. The patient 
with both epilepsy and migraine might favor topiramate or 
valproate, drugs which are efficacious for both conditions. 
Patients receiving other AEDs or non-AED co-medications 
interacting with AEDs are at particular risk for adverse ef-
fects of treatment and adverse consequences. Hormonal con-
traceptive and anticoagulants are perhaps the best known 
non-AED medications resulting in hazardous interactions 
with enzyme-inducing AEDs (EIAEDs), but other inducible 
medications such as lipid-lowering drugs and anti-hyper-
tensives may result in catastrophic cardiovascular and cere-
brovascular consequences if rendered less effective by 
EIAEDs. 
AED TITRATION AND TARGET DOSE 
  AED dosing must be individualized to achieve optimal 
results. The usual strategy is to titrate the AED toward a tar-
get dose that has proven effective for most individuals in 
pivotal clinical studies and in subsequent clinical experience. 
Dose adjustment can then be made in the event of adverse 
drug reactions or recurrent seizures. If the endpoint of sei-
zure freedom is preserved, maintaining a lower but clinically 
therapeutic AED dosage and level (if obtained) is entirely 
acceptable. If a patient continues to experience breakthrough 
seizures, raising the AED dose to the maximal dose tolerated 
is sometimes necessary, although recent evidence demon-
strates that only a minority of patients become seizure-free 
when dosed above the usual population range, so a practical 
viewpoint of treatment futility should be realized when pa-
tients experience frequent breakthrough seizures despite 
adequate AED dosages [14].
 Therapeutic change should be 
strongly considered when seizure-freedom is not maintained 
at AED doses which are effective for most patients. 
AED SEQUENCING AND POLYTHERAPY CONSID-
ERATIONS 
  Overlapping AEDs in transitional polytherapy (where the 
baseline AED is maintained at the current dose to limit 
breakthrough seizures, the newly added AED is titrated to a 
protective dose, then the original drug is tapered and discon-
tinued) is the preferred method when introducing a new AED 
monotherapy. Abruptly stopping the existing AED increases 
the risk of seizures while introducing the new adjunctive 
AED too rapidly may induce adverse effects that taint the 
patient’s perception of what could otherwise be an effective 
therapy. Recently, an expert consensus panel was convened 
to address the issue of how best to convert between AED 
monotherapies when initial monotherapy fails due to lack of 
efficacy or tolerability, utilizing the Delphi model of deter-
mining consensus on strategies for best practice [33]. The 
experts agreed on a basic principle to taper an existing base-
line AED only after a presumably efficacious dose of the 
newly planned adjunctive AED is reached. It was felt that 
application of this principle should be modified by occur-
rence of adverse effects possibly attributable to the existing 
drug, in which case earlier or more rapid tapering of the ex-
isting drug should be considered. The experts agreed that 
seizure-free patients benefit from slower tapering in smaller 
decrements than would be typical for patients with seizures 
not controlled by the existing AED. 
  Most patients should receive two sequential AED mono-
therapies with differing mechanisms of action prior to at-
tempting chronic polytherapy. In general, a similar strategy 
to that agreed upon by the expert panel for monotherapy 
conversions should also be used when initiating addition of a 
second (or third) adjunctive AED for use as chronic polythe-
rapy. A recent trial well illustrated the potential for increased 
toxicity with adjunctive AED therapy [25]. This randomized, 
perspective, adjunctive topiramate study design directly ad-
dressed which strategy for addressing adverse effects emerg-
ing during adjunctive AED titration was most efficacious 
and tolerable, by randomizing subjects to two treatment 
arms; (1) a “Flex Dose” titration group, in which investiga-112    Current Neuropharmacology, 2009, Vol. 7, No. 2  Erik K. St. Louis 
tors were permitted to reduce the baseline AED as needed to 
permit titration of adjunctive topiramate; and (2) a “Fixed 
Dose” titration group, where investigators were not permit-
ted to adjust the baseline AED for titration-emergent adverse 
effects (similar to the restrictions required in most pivotal 
labeling studies for the newer AEDs as adjunctive therapy); 
if investigators needed to adjust the baseline co-therapy, the 
patient was exited from randomized treatment. The percen-
tage of patients exiting randomized treatment due to adverse 
effects was the primary study endpoint. The “Flex Dose” 
group achieved higher target doses of adjunctive topiramate, 
while the “Fixed Dose” group had nearly twice as many sub-
jects drop-out for intolerable adverse effects [25]. This data 
suggests that it may be best to reduce the baseline AED to 
minimize adverse effects emerging during the titration of a 
new adjunctive therapy, to enable an adequate therapeutic 
trial of the new adjunctive AED therapy. The adjunctive 
AED can be further increased as needed to achieve optimal 
therapeutic doses in transition toward a new monotherapy 
when the new adjunctive AED demonstrates a meaningful 
therapeutic effect [4]. 
  When utilizing polytherapy, the clinician must be know-
ledgeable about the potential for pharmacokinetic and phar-
macodynamic AED interactions, which influence the risk of 
developing adverse effects. While an exhaustive review of 
drug interactions is beyond the scope of this article, a few 
illustrative scenarios will suffice to make this important point. 
In general, the main pharmacokinetic interactions to consider 
in AED polytherapy are potential Cytochrome P450 meta-
bolism competition, and protein binding and displacement. 
Co-administration of the enzyme-inducing AEDs (i.e., phe-
nobarbital, phenytoin, carbamazepine) with inducible AEDs 
(such as lamotrigine, topiramate, or tiagabine) increases and 
hastens the metabolism of the inducible AED. In complex 
polytherapy regimens, reducing the dose of enzyme-indu-
cing AEDs (such as carbamazepine, phenytoin, or the barbi-
turates) will “de-induce” the regimen, thereby increasing the 
serum concentrations of highly inducible AEDs (such as 
lamotrigine and topiramate), leading to optimized pharmaco-
kinetics of the inducible AED and improved seizure control 
in some instances [1].
 Conversely, when an inhibitor such as 
valproate is given with lamotrigine, there is a greater chance 
of serious rash than when lamotrigine is given with enzyme-
inducing AEDs [23]. Two recent studies of vulnerable insti-
tutionalized patients well illustrate the complex pharmacoki-
netic issues that can arise in polytherapy. In these studies of 
elderly nursing home and multiply handicapped patients, 
common use of undesirable pharmacokinetic AED combina-
tions was found, especially phenytoin/phenobarbital and 
phenytoin/valproate polytherapy, [12,20]. The interactions 
between these AEDs are bidirectional, complex, and varia-
ble, leading to unpredictable increases or decreases in drug 
concentrations, and in an institutionalized patient population 
with common co-morbid hypoalbuminemia, free phenytoin 
levels should be monitored to enable appropriate co-therapy 
adjustments to avoid toxicity. Switching to a regimen with 
less likelihood of complex interactions should be strongly 
considered in such instances. An extensive, superb review of 
AED drug interactions is found in the recent work by Patsa-
los and colleagues [26].
 
  Pharmacodynamic adverse effects are especially difficult 
to avoid when using polytherapy, as dose-related neurotoxic 
and cognitive adverse effects are more prevalent in polythe-
rapy.
 Cognitive impairments commonly accompany polythe-
rapy and are often subtle and difficult to identify without 
specifically questioning the patient. While standard office 
assessment of cognition often shows minimal impact, de-
tailed neuropsychological and electrophysiological measures 
often show impairments in attention, concentration, execu-
tive function, and memory in patients receiving AED therapy 
[22,29,34,35]. Some adverse effects such as sedation, cogni-
tive impairments, gait disturbance, and hair changes are con-
sistently underreported unless patients are specifically ques-
tioned about the presence or absence of these symptoms. 
Clinicians should consider routinely using adverse events 
screening instruments such as the AEP to identify AED ad-
verse effects during office visits, especially for patients re-
ceiving polytherapy. Some AEDs have a greater tendency to 
cause pharmacodynamic adverse effects when co-adminis-
tered with other AEDs; for example, there is a greater chance 
for adverse effects when utilizing topiramate as adjunctive 
therapy than when it is administered as monotherapy [27,30]. 
AED THERAPEUTIC MONITORING: TREAT THE 
PATIENT, NOT THE LEVEL 
  An intimately related issue to clinical toxicity meriting 
discussion is “laboratory” toxicity, that is, when AED blood 
levels fall above established “normal” therapeutic ranges. 
Philosophies on the use of AED blood level monitoring dif-
fer, but most agree that blood levels should be considered 
only a guideline to treatment in most cases. AED levels 
should not be perceived as an absolute indication for altering 
AED dosing, divorced from clinical judgment of the pa-
tient’s seizure control or adverse effects. Blood level moni-
toring can help guide therapy, but so-called “therapeutic” 
levels are derived from treatment of populations. An individ-
ual patient may require a lower or higher intensity of AED 
therapy to achieve optimal results. In general, AED levels 
are most useful when testing a clinical hypothesis. “Routine” 
or scheduled levels should be generally discouraged, an ex-
ception being chronic phenytoin therapy in institutionalized 
patients (where “zero-order” kinetics from non-linear hepatic 
metabolism may lead to drug accumulation and toxicity). 
AED blood level monitoring is further reviewed in the next 
article in this series. 
PREVENTION OF IDIOSYNCRATIC ADVERSE EF-
FECTS OF AEDS 
  Unfortunately, accurate prediction of the development of 
idiosyncratic toxicities of AEDs is not currently possible. 
The highest risk of idiosyncratic reactions associated with 
most older AEDs such as serious rash, hepatotoxicity and 
hematologic dyscrasias is during the first 6-12 months of 
therapy, and extremely rare thereafter, so that routine moni-
toring for these problems is rarely necessary in otherwise 
healthy patients. Intermittent blood testing for monitoring of 
liver function tests and hematologic functions is reasonable, 
although not of proven value; consider obtaining baseline 
AST/SGOT and complete blood count (CBC) with repeated 
measures at 1, 3, and 6 months following initiation of thera-
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before initiation of carbamazepine and oxcarbazepine (which 
may result in hyponatremia) with repeat testing after two 
months, perhaps with earlier or more frequent testing in el-
derly patients or those receiving sodium-wasting diurectics. 
If felbamate is used, baseline and weekly liver function and 
CBC testing is indicated per package insert labeling. Most 
experts continue such extensive monitoring until at least sev-
eral months of clinical and laboratory stability have been 
reached, given the potential for fatal aplastic anemia and 
hepatotoxicity, and then continue periodic monitoring the-
reafter. 
  There is mounting concern that patients on chronic thera-
py with older AEDs are at risk for bone density loss and 
fractures. Enzyme-inducing AEDs (EIAEDS: i.e., carbamaze-
pine, phenytoin, phenobarbital, primidone, oxcarbazepine, 
and possibly high dose topiramate) have the potential to de-
crease bone density through secondary hypoparathyroidism 
and decreased Vitamin D levels, and some evidence suggests 
that non-inducers such as valproate also lead to decreased 
bone density [36].
 Many epileptologists are now proactively 
counseling patients who have received therapy with older 
AEDs for several years about the emerging risk of reduced 
bone density, suggesting measuring bone mineral densitome-
try, and placing patients on supplemental calcium. Offering 
patients the opportunity to attempt withdrawal from older 
AEDs if they have been seizure free for several years (and if 
they are at low risk of seizure recurrence), or transitioning 
them to a newer AED lacking enzyme-inducing pro-perties 
(although there is little evidence of long-term safety for bone 
health with newer AEDs) may also be considered. 
  Women of child bearing potential (WCBP) are at risk for 
two worrisome AED-related adverse effects: pregnancy due 
to oral contraceptive failure, and AED-induced fetal terato-
genesis. Avoiding EIAEDs in WCBP whenever possible is 
prudent to avoid hormonal contraceptive failure, and coun-
seling WCBP about the hazard of contraceptive failure with 
EIAEDs is important. WCBP should be instructed to utilize 
double-barrier contraception in addition to their hormonal 
methods when receiving EIAEDs. Prior to a planned preg-
nancy, weaning the WCBP from AEDs when she is seizure-
free and at low risk of seizure recurrence, or utilizing mono-
therapy when AED therapy is necessary whenever feasible, 
is especially important in WCBP since polytherapy use has 
been linked to teratogenesis. While there is not yet unequi-
vocal evidence regarding AED safety or hazards during first 
trimester exposure in pregnancy, available evidence suggests 
that phenobarbital and valproate should be avoided when 
possible (unless these agents have resulted in complete sei-
zure-freedom, in which case many experts still agree that the 
most desirable AED to maintain during pregnancy is the 
AED which has resulted in seizure control). Although no 
certain evidence basis exists. most agree that WCBP taking 
AEDs should receive folic acid 1 milligram daily (or a pre-
natal multivitamin), especially those on EIAEDs. Some ex-
perts recommend high dose folic acid for women receiving 
valproate, up to 4 milligrams daily. 
  Chronic phenytoin exposure is of particular concern, giv-
en its relatively common association with cosmetic adverse 
effects including gingival hyperplasia (which may be severe 
enough to warrant repeated gingivectomies), and the rare but 
real potential of axonal peripheral neuropathy and irreversi-
ble cerebellar ataxia. Many experts now feel that because of 
these risks, phenytoin use should be for a relatively short 
term (i.e., no longer than a few years), after which time the 
patient can be offered the opportunity to transition to another 
AED if continued therapy is necessary. 
  One additional idiosyncratic toxicity meriting mention 
here is risk of serious rash with lamotrigine, which appears 
to be related to several factors, at least one of which is mod-
ifiable: pediatric age, concurrent valproic acid therapy, and 
overly rapid initial titration of lamotrigine. When initiating 
lamotrigine, paying strict attention to AED co-medications 
and adhering strictly to the recommended package insert 
titration instructions is required. 
CONCLUSIONS 
  Epilepsy QOL research suggests that too little clinician 
attention has been focused upon the interictal state. One crit-
ical determinant of QOL in epilepsy patients is whether they 
suffer from adverse effects of AED therapy. Research has 
shown that identification of AED adverse effects is aided by 
using the Adverse Events Profile (AEP), a validated clinical 
tool easily completed by patients in the office setting within 
a few minutes, and that considering this information leads to 
appropriate alterations in AED therapy that may improve 
patient QOL. Strategies for reducing common dose-related 
“neurotoxic” adverse effects include optimal AED selection, 
titration, co-therapy reduction, utilizing monotherapy, and 
elimination of polytherapy when feasible. In refractory epi-
lepsy, utilizing drug-sparing therapies such as epilepsy sur-
gery, VNS or dietary therapies, or diagnosis and treatment of 
co-morbid primary sleep disorders may minimize AED doses 
and drug load, thereby minimizing adverse effects. Idiosyn-
cratic adverse effects cannot be reliably predicted with cur-
rent clinical tools and strategies for prevention of specific 
idiosyncratic adverse effects such as teratogenicity and bone 
loss are unfortunately lacking, but treating women of child 
bearing potential receiving AED therapy with folic acid and 
daily supplemental calcium is reasonable (the latter should 
also be considered even for men receiving chronic AEDs 
with risk factors for osteoporosis). Vigilance toward the cur-
rent presence and future possible evolution of adverse effects 
of epilepsy therapy should be considered a chief responsibili-
ty of epilepsy clinicians, since proactive AED alteration may 
effect improvements in patient QOL. 
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